Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
Completed
Hutchison Medipharma Limited
Phase 1
a multicenter, open-label phase Ib study to determine the safety, tolerability and
preliminary efficacy of Sulfatinib 300 mg once a day in treating advanced neuroendocrine
tumors
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Recruiting
Hutchison Medipharma Limited
Phase 1/Phase 2
Primary Objective Dose Escalation:
To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors
and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
Primary Objective Dose Expansion:
To evaluate the anticancer activity of surufatinib in patients with advanced Biliary Tract
Cancer (BTC), patients with advanced pancreatic neuroendocrine tumors (pNETs), patients with
locally advanced, unresectable, metastatic extra-pancreatic neuroendocrine tumors (EP-NETs),
and patients with soft tissue sarcomas (STS) treated at a dose of 300 mg QD.
Secondary Objective:
To evaluate the pharmacokinetic profile of multiple dose surufatinib in patients with
advanced solid tumors and to evaluate the anti cancer activity of surufatinib in patients
with advanced solid tumors.
Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Active, not recruiting
Hutchison Medipharma Limited
Phase 3
A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the
efficacy of Surufatinib 300 mg once a day in treating advanced extrapancreatic neuroendocrine
tumors.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
